Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients With Small Cell Lung Cancer (SCLC) or Other Solid Tumors

Trial Profile

A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients With Small Cell Lung Cancer (SCLC) or Other Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs APG 1252 (Primary)
  • Indications Brain metastases; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Ascentage Pharma
  • Most Recent Events

    • 13 Nov 2018 Pooled results from three phase I studies presented in an Ascentage Pharma media release.
    • 13 Nov 2018 According to an Ascentage Pharma media release, data from the study has been presented at the Asia Conference on Lung Cancer 2018 (ACLC).
    • 05 Jun 2018 Results (n=13) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top